These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 22476757)
1. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Hayashi M; Yamamoto Y; Ibusuki M; Fujiwara S; Yamamoto S; Tomita S; Nakano M; Murakami K; Iyama K; Iwase H Ann Surg Oncol; 2012 Sep; 19(9):3042-9. PubMed ID: 22476757 [TBL] [Abstract][Full Text] [Related]
2. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324 [TBL] [Abstract][Full Text] [Related]
3. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419 [TBL] [Abstract][Full Text] [Related]
4. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090 [TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600 [TBL] [Abstract][Full Text] [Related]
7. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200 [TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606 [TBL] [Abstract][Full Text] [Related]
10. Early Evaluation of Relative Changes in Tumor Stiffness by Shear Wave Elastography Predicts the Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Jing H; Cheng W; Li ZY; Ying L; Wang QC; Wu T; Tian JW J Ultrasound Med; 2016 Aug; 35(8):1619-27. PubMed ID: 27302898 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y J BUON; 2013; 18(1):57-63. PubMed ID: 23613389 [TBL] [Abstract][Full Text] [Related]
12. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer. Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323 [TBL] [Abstract][Full Text] [Related]
13. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620 [TBL] [Abstract][Full Text] [Related]
14. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975 [TBL] [Abstract][Full Text] [Related]
16. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900 [TBL] [Abstract][Full Text] [Related]
17. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T J BUON; 2015; 20(1):45-9. PubMed ID: 25778295 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496 [TBL] [Abstract][Full Text] [Related]
20. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]